CN104159607A - 用于治疗致癌病毒多肽阳性肿瘤的多核苷酸 - Google Patents

用于治疗致癌病毒多肽阳性肿瘤的多核苷酸 Download PDF

Info

Publication number
CN104159607A
CN104159607A CN201380012419.2A CN201380012419A CN104159607A CN 104159607 A CN104159607 A CN 104159607A CN 201380012419 A CN201380012419 A CN 201380012419A CN 104159607 A CN104159607 A CN 104159607A
Authority
CN
China
Prior art keywords
deletion
point mutation
oncogenic
polypeptide
nucleotide sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201380012419.2A
Other languages
English (en)
Chinese (zh)
Inventor
J.H.李
D.W.弗米尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanford Health
Original Assignee
Sanford Research USD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanford Research USD filed Critical Sanford Research USD
Priority to CN201910216555.2A priority Critical patent/CN110042110A/zh
Publication of CN104159607A publication Critical patent/CN104159607A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10042—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN201380012419.2A 2012-01-24 2013-01-23 用于治疗致癌病毒多肽阳性肿瘤的多核苷酸 Pending CN104159607A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910216555.2A CN110042110A (zh) 2012-01-24 2013-01-23 用于治疗致癌病毒多肽阳性肿瘤的多核苷酸

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261590089P 2012-01-24 2012-01-24
US61/590,089 2012-01-24
PCT/US2013/022696 WO2013112549A1 (en) 2012-01-24 2013-01-23 Polynucleotides for treating oncogenic viral polypeptide positive tumors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201910216555.2A Division CN110042110A (zh) 2012-01-24 2013-01-23 用于治疗致癌病毒多肽阳性肿瘤的多核苷酸

Publications (1)

Publication Number Publication Date
CN104159607A true CN104159607A (zh) 2014-11-19

Family

ID=48873849

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201380012419.2A Pending CN104159607A (zh) 2012-01-24 2013-01-23 用于治疗致癌病毒多肽阳性肿瘤的多核苷酸
CN201910216555.2A Pending CN110042110A (zh) 2012-01-24 2013-01-23 用于治疗致癌病毒多肽阳性肿瘤的多核苷酸

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201910216555.2A Pending CN110042110A (zh) 2012-01-24 2013-01-23 用于治疗致癌病毒多肽阳性肿瘤的多核苷酸

Country Status (10)

Country Link
US (3) US9492526B2 (enExample)
EP (2) EP2806889B1 (enExample)
JP (2) JP6219849B2 (enExample)
KR (1) KR102195196B1 (enExample)
CN (2) CN104159607A (enExample)
DK (1) DK2806889T3 (enExample)
ES (1) ES2646590T3 (enExample)
HK (1) HK1203833A1 (enExample)
IN (1) IN2014DN06118A (enExample)
WO (1) WO2013112549A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109891405A (zh) * 2016-11-11 2019-06-14 谷歌有限责任公司 基于用户装置的消费模式来修改视频内容在用户装置上的呈现的方法、系统和介质
CN116425839A (zh) * 2023-04-03 2023-07-14 深圳锦时生物科技有限公司 人乳头瘤病毒多肽及其应用

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2811093T3 (es) 2014-11-13 2021-03-10 Univ Geneve Arenavirus trisegmentados como vectores de vacunas
HK1246183A1 (zh) 2015-06-10 2018-09-07 Hookipa Biotech Gmbh Hpv疫苗
WO2017076988A1 (en) 2015-11-04 2017-05-11 Hookipa Biotech Ag Vaccines against hepatitis b virus
EP3373959B1 (en) 2015-11-12 2022-06-29 Hookipa Biotech GmbH Arenavirus particles as cancer vaccines
JP2019505512A (ja) 2016-01-08 2019-02-28 バッシボディ アクスイェ セルスカプ 治療用抗癌ネオエピトープワクチン
GB201605210D0 (en) 2016-03-29 2016-05-11 Oxford Immunotec Ltd Assay
JP2019517522A (ja) * 2016-06-03 2019-06-24 エトゥビクス コーポレーション ヒトパピローマウイルス（ｈｐｖ）関連疾患の処置のための組成物及び方法
CN106655327A (zh) * 2016-10-18 2017-05-10 云南中烟工业有限责任公司 一种压缩式充电装置
SG11202008539YA (en) 2018-03-06 2020-10-29 Precigen Inc Human papillomavirus vaccines and uses of the same
IL296509A (en) 2020-03-16 2022-11-01 Univ North Carolina Chapel Hill Preparations and methods for selective detection of tumor-derived viral DNA
WO2021205027A1 (en) 2020-04-09 2021-10-14 Vaccibody As Individualized therapeutic anticancer vaccine
AU2021281910C1 (en) * 2020-05-25 2024-09-19 Genematrix Inc. Structurally modified chimeric polypeptide of human papillomavirus, recombinant protein comprising same polypeptide, and use of same protein
KR102712588B1 (ko) * 2020-05-25 2024-10-02 (주)진매트릭스 사람 파필로마바이러스의 구조적으로 변형된 키메라 폴리펩타이드 및 그 폴리펩타이드를 포함하는 재조합 단백질 및 그 단백질의 용도

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999061608A2 (en) * 1998-05-26 1999-12-02 Institute Of Molecular And Cell Biology Polypeptides from creb binding protein and related protein p300 for use in transcriptional regulation
CN1276833A (zh) * 1997-08-22 2000-12-13 史密丝克莱恩比彻姆生物有限公司 疫苗
CN101688223A (zh) * 2007-05-15 2010-03-31 特兰斯吉恩股份有限公司 用于多基因表达的载体

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2499837C (en) * 2002-10-03 2013-12-03 Wyeth Holdings Corporation Human papillomavirus polypeptides and immunogenic compositions
WO2010129339A2 (en) * 2009-04-28 2010-11-11 The Johns Hopkins University Compositions and methods for enhancing antigen-specific immune responses
CN102002105B (zh) * 2009-09-03 2013-01-23 中国疾病预防控制中心病毒病预防控制所 Hpv 16型e7e6融合蛋白基因、表达载体、方法、细胞和用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1276833A (zh) * 1997-08-22 2000-12-13 史密丝克莱恩比彻姆生物有限公司 疫苗
WO1999061608A2 (en) * 1998-05-26 1999-12-02 Institute Of Molecular And Cell Biology Polypeptides from creb binding protein and related protein p300 for use in transcriptional regulation
CN101688223A (zh) * 2007-05-15 2010-03-31 特兰斯吉恩股份有限公司 用于多基因表达的载体

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANNA-MARIJA HELT ET AL.: "Inactivation of both the Retinoblastoma Tumor Suppressor and p21 by the Human Papillomavirus Type 16 E7 Oncoprotein Is Necessary To Inhibit Cell Cycle Arrest in Human Epithelial Cells", 《JOURNAL OF VIROLOGY》 *
BRYANT G. WIEKING ET AL.: "A Non-oncogenic HPV 16 E6/E7 Vaccine Enhances Treatment of HPV Expressing Tumors", 《CANCER GENE THERAPY》 *
K W JEONG ET AL.: "Human papillomavirus type 16 E6 protein interacts with cystic fibrosis transmembrane regulator-associated ligand and promotes E6-associated protein-mediated ubiquitination and proteasomal degradation", 《ONCOGENE》 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109891405A (zh) * 2016-11-11 2019-06-14 谷歌有限责任公司 基于用户装置的消费模式来修改视频内容在用户装置上的呈现的方法、系统和介质
US11758228B2 (en) 2016-11-11 2023-09-12 Google Llc Methods, systems, and media for modifying the presentation of video content on a user device based on a consumption of the user device
CN109891405B (zh) * 2016-11-11 2023-09-26 谷歌有限责任公司 基于用户装置的消费模式来修改视频内容在用户装置上的呈现的方法、系统和介质
US12170819B2 (en) 2016-11-11 2024-12-17 Google Llc Methods, systems, and media for modifying the presentation of video content on a user device based on a consumption of the user device
CN116425839A (zh) * 2023-04-03 2023-07-14 深圳锦时生物科技有限公司 人乳头瘤病毒多肽及其应用

Also Published As

Publication number Publication date
EP2806889A1 (en) 2014-12-03
EP2806889B1 (en) 2017-08-16
IN2014DN06118A (enExample) 2015-08-14
JP2015506179A (ja) 2015-03-02
CN110042110A (zh) 2019-07-23
EP2806889A4 (en) 2016-04-20
US9969779B2 (en) 2018-05-15
US9492526B2 (en) 2016-11-15
JP2018038405A (ja) 2018-03-15
KR102195196B1 (ko) 2020-12-28
US20180237477A1 (en) 2018-08-23
EP3269387B1 (en) 2019-07-17
KR20140131929A (ko) 2014-11-14
HK1203833A1 (en) 2015-11-06
US20150023996A1 (en) 2015-01-22
DK2806889T3 (da) 2017-11-20
JP6219849B2 (ja) 2017-10-25
ES2646590T3 (es) 2017-12-14
WO2013112549A1 (en) 2013-08-01
JP6655051B2 (ja) 2020-02-26
US20160376324A1 (en) 2016-12-29
EP3269387A1 (en) 2018-01-17

Similar Documents

Publication Publication Date Title
US9969779B2 (en) Polynucleotides for treating oncogenic viral polypeptide positive tumors
JP6688535B2 (ja) ワクチン組成物
KR102351555B1 (ko) Hpv 및 관련 질환용 면역 증강 치료 백신
CN103998604B (zh) Hbv聚合酶突变体
JP6325459B2 (ja) 腫瘍関連異種抗原を発現するアデノウイルス
JP2019068852A (ja) 治療用ｈｐｖ１８ワクチン
Singh et al. An alphavirus-based therapeutic cancer vaccine: from design to clinical trial
JP2020527029A (ja) Ｈｉｖ抗原をコードするポックスウイルスベクターおよびその使用方法
US20240415951A1 (en) Lentiviral vector for expression of human papillomavirus (hpv) antigens and its implementation in the treatment of hpv induced cancers
JP2024532853A (ja) 治療用パピローマウイルスワクチン
Báez-Astúa et al. Low-dose adenovirus vaccine encoding chimeric hepatitis B virus surface antigen-human papillomavirus type 16 E7 proteins induces enhanced E7-specific antibody and cytotoxic T-cell responses
Liao et al. A novel “priming-boosting” strategy for immune interventions in cervical cancer
WO2024023135A1 (en) Lentiviral vectors for expression of human papillomavirus (hpv) antigens and its implementation in the treatment of hpv induced cancers
CN118354790A (zh) 用于表达人乳头瘤病毒(hpv)抗原的慢病毒载体及其在治疗hpv诱发癌症中的应用

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1203833

Country of ref document: HK

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20161202

Address after: South Dakota

Applicant after: Sanford health

Address before: South Dakota

Applicant before: SANFORD RESEARCH/USD

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20141119

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1203833

Country of ref document: HK